Can pheochromocytoma cause hypokalemia?

Can Pheochromocytoma Cause Hypokalemia?

Yes, pheochromocytoma can cause hypokalemia, though this is an uncommon presentation that should raise clinical suspicion for specific underlying mechanisms.

Mechanisms of Hypokalemia in Pheochromocytoma

Hypokalemia in pheochromocytoma occurs through several distinct pathways:

Primary Mechanisms

Epinephrine-mediated intracellular potassium shift is the most direct mechanism. Research demonstrates a significant negative correlation between plasma epinephrine concentrations and serum potassium levels in pheochromocytoma patients 1. Epinephrine infusions in normal subjects induce hypokalemia by driving potassium into cells via beta-2 adrenergic receptor activation, and this same mechanism operates in epinephrine-secreting pheochromocytomas.

Secondary hyperaldosteronism can develop when catecholamine excess stimulates the renin-angiotensin-aldosterone system. Case reports document pheochromocytomas presenting with hyperreninemia and hyperaldosteronism leading to hypokalemia 2.

Ectopic hormone production represents a rare but important mechanism. Pheochromocytomas can co-secrete ACTH (causing Cushing's syndrome with hypokalemia) 3 or vasoactive intestinal peptide (VIP), which causes severe watery diarrhea with profound hypokalemia and metabolic acidosis 4.

Clinical Recognition

Key Diagnostic Features

When you encounter a patient with suspected pheochromocytoma and hypokalemia, look for:

• Predominant epinephrine secretion: Check both plasma and urinary fractionated metanephrines, specifically looking for elevated metanephrine (epinephrine metabolite) rather than normetanephrine 1
• Vomiting or diarrhea: These can cause hypokalemia, but if hypokalemia persists after correction and cessation of GI losses, consider direct catecholamine effects 1
• Cushingoid features: Facial plethora, central obesity, proximal weakness, and hyperglycemia suggest ACTH co-secretion 3
• Severe watery diarrhea with metabolic acidosis: This constellation with hypokalemia suggests VIP co-secretion 4

Important Clinical Pitfall

Do not dismiss pheochromocytoma based on absence of hypertension. While most pheochromocytomas present with hypertension, rare cases present with chronic hypotension 5. The presence of hypokalemia with palpitations, even without hypertension, warrants biochemical screening.

Diagnostic Approach

Following the 2014 Endocrine Society guidelines 6:

1. Initial biochemical testing should include plasma free metanephrines or urinary fractionated metanephrines
2. Specifically evaluate the epinephrine component when hypokalemia is present
3. Check for co-secreted hormones if clinical features suggest:
   • Measure ACTH and cortisol if cushingoid features present
   • Measure VIP if severe diarrhea with metabolic acidosis
   • Assess renin and aldosterone if marked hypokalemia without other explanation

Management Implications

Preoperative Considerations

The presence of hypokalemia requires specific attention during preoperative preparation 7:

• Correct hypokalemia before surgery to reduce arrhythmia risk, as catecholamine excess already predisposes to ventricular arrhythmias 8
• Standard alpha-blockade remains first-line: Phenoxybenzamine (10-20 mg two to three times daily) or doxazosin (2-4 mg two to three times daily) for 10-14 days preoperatively 9, 10
• Liberal salt and fluid intake is particularly important, as the vasoconstricted state causes intravascular volume depletion 7
• Beta-blockade only after adequate alpha-blockade if arrhythmias present 9, 10

Intraoperative Monitoring

Patients with hypokalemia and pheochromocytoma require heightened vigilance for arrhythmias during surgery 7. Have intravenous propranolol readily available for ventricular arrhythmias and lidocaine as backup 7.

Prognosis and Follow-up

After successful tumor resection, hypokalemia typically resolves completely if it was directly related to the pheochromocytoma 3, 1, 11. Persistent hypokalemia postoperatively suggests either:

• Incomplete tumor resection
• Metastatic disease
• Coexisting adrenal pathology (such as concurrent aldosterone-producing adenoma) 11

All patients require lifelong biochemical follow-up to detect recurrent or metastatic disease, as approximately 16% of apparently benign pheochromocytomas recur during long-term follow-up 7.